Citius Oncology (CTOR) Other Operating Expenses (2023 - 2026)

Citius Oncology (CTOR) has reported Other Operating Expenses for 4 consecutive years, with $4.2 million the latest figure, recorded in Q2 2026.

• On a quarterly basis, Other Operating Expenses rose 172.53% year-over-year to $4.2 million in Q2 2026; TTM through Jun 2026 was $14.8 million, a 67.31% increase from a year earlier, with the FY2025 full-year figure at $6.1 million, up 8.25% from the prior year.
• Other Operating Expenses was $4.2 million for Q2 2026 at Citius Oncology, down from $4.7 million in the prior quarter.
• Over five years, Other Operating Expenses peaked at $4.7 million in Q1 2026 and troughed at $1.2 million in Q4 2024.
• A 4-year average of $2.8 million and a median of $2.4 million in 2024 frame the typical range for Other Operating Expenses.
• The widest YoY moves for Other Operating Expenses: up 224.98% in 2025, down 65.4% in 2025.
• Over 4 years, Other Operating Expenses stood at $1.5 million in 2023, then declined by 17.01% to $1.2 million in 2024, then surged by 224.98% to $4.0 million in 2025, then advanced by 5.27% to $4.2 million in 2026.
• The last three Other Operating Expenses figures came in at $4.2 million (Q2 2026), $4.7 million (Q1 2026), and $4.0 million (Q4 2025), per Business Quant data.